# Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma

> **NCT00007852** · PHASE2 · COMPLETED · sponsor: **University of Nebraska** · enrollment: 44 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** rituximab
- **DRUG:** carmustine
- **DRUG:** cytarabine
- **DRUG:** etoposide
- **DRUG:** melphalan
- **PROCEDURE:** autologous hematopoietic stem cell transplantation

## Key facts

- **NCT ID:** NCT00007852
- **Lead sponsor:** University of Nebraska
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-09-01
- **Primary completion:** 2002-01-01
- **Final completion:** 2011-01-01
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2023-09-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00007852

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00007852, "Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00007852. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*